Published in Nat Rev Cancer on October 01, 2001
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol (2010) 9.15
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res (2009) 3.61
Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol (2008) 3.56
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol (2009) 3.13
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A (2010) 2.69
A history of prostate cancer treatment. Nat Rev Cancer (2002) 2.46
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res (2010) 2.42
Sex hormone-dependent tRNA halves enhance cell proliferation in breast and prostate cancers. Proc Natl Acad Sci U S A (2015) 2.35
Mechanisms mediating androgen receptor reactivation after castration. Urol Oncol (2008) 2.35
Genomic androgen receptor-occupied regions with different functions, defined by histone acetylation, coregulators and transcriptional capacity. PLoS One (2008) 2.18
Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor. Cancer Cell (2007) 2.14
Modeling cancer progression via pathway dependencies. PLoS Comput Biol (2008) 2.12
A network biology approach to prostate cancer. Mol Syst Biol (2007) 2.07
Androgen receptor signaling in prostate cancer development and progression. J Carcinog (2011) 1.90
The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res (2009) 1.88
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy. Eur Urol (2013) 1.85
miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice. PLoS One (2009) 1.84
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc Natl Acad Sci U S A (2006) 1.78
SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2011) 1.77
Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells. Proc Natl Acad Sci U S A (2006) 1.77
Stem cells in prostate cancer initiation and progression. J Clin Invest (2007) 1.76
Mutation of the androgen receptor causes oncogenic transformation of the prostate. Proc Natl Acad Sci U S A (2005) 1.73
Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer (2005) 1.73
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol (2010) 1.70
Myc confers androgen-independent prostate cancer cell growth. J Clin Invest (2003) 1.65
Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone. Mol Cell Biol (2007) 1.65
Tissue-selective therapy of cancer. Br J Cancer (2003) 1.59
Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Mol Cancer Ther (2008) 1.59
The complexity of prostate cancer: genomic alterations and heterogeneity. Nat Rev Urol (2012) 1.59
The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Res (2008) 1.58
Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol. Mol Cell Endocrinol (2008) 1.57
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia (2004) 1.56
Integration of regulatory networks by NKX3-1 promotes androgen-dependent prostate cancer survival. Mol Cell Biol (2011) 1.56
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer (2015) 1.55
Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer (2002) 1.53
Behavioral stress accelerates prostate cancer development in mice. J Clin Invest (2013) 1.52
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A (2006) 1.52
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev (2011) 1.51
Mifepristone inhibits GRβ coupled prostate cancer cell proliferation. J Urol (2012) 1.51
Inorganic arsenic and human prostate cancer. Environ Health Perspect (2008) 1.47
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells. Proc Natl Acad Sci U S A (2005) 1.46
The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol Ther (2010) 1.46
Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells. Mol Cell Biol (2006) 1.46
Identification of Androgen Receptor Splice Variants in the Pten Deficient Murine Prostate Cancer Model. PLoS One (2015) 1.43
Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol (2005) 1.42
Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice. Mol Cancer Ther (2010) 1.42
Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One (2015) 1.41
APPL1: role in adiponectin signaling and beyond. Am J Physiol Endocrinol Metab (2008) 1.41
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer Res (2010) 1.39
Profiling alternatively spliced mRNA isoforms for prostate cancer classification. BMC Bioinformatics (2006) 1.39
Peroxisome proliferator-activated receptor gamma regulates E-cadherin expression and inhibits growth and invasion of prostate cancer. Mol Cell Biol (2006) 1.37
Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res (2010) 1.37
Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem (2010) 1.36
NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol (2009) 1.35
Regression of human prostate tumors and metastases in nude mice following treatment with the recombinant oncolytic vaccinia virus GLV-1h68. J Biomed Biotechnol (2010) 1.35
Androgen receptor on the move: boarding the microtubule expressway to the nucleus. Cancer Res (2012) 1.35
LEF1 in androgen-independent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res (2009) 1.34
Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol (2006) 1.33
MicroRNAs and prostate cancer. J Cell Mol Med (2008) 1.33
Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells. Am J Pathol (2006) 1.33
BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol (2005) 1.32
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer (2011) 1.32
MUC1 oncoprotein is a druggable target in human prostate cancer cells. Mol Cancer Ther (2009) 1.30
AFAP-110 is overexpressed in prostate cancer and contributes to tumorigenic growth by regulating focal contacts. J Clin Invest (2007) 1.30
FKBP51 and Cyp40 are positive regulators of androgen-dependent prostate cancer cell growth and the targets of FK506 and cyclosporin A. Oncogene (2009) 1.29
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Androgen receptor signaling and mutations in prostate cancer. Asian J Androl (2010) 1.27
A new trick of an old molecule: androgen receptor splice variants taking the stage?! Int J Biol Sci (2011) 1.27
Molecular mechanisms of castration-resistant prostate cancer progression. Future Oncol (2009) 1.26
Negative modulation of androgen receptor transcriptional activity by Daxx. Mol Cell Biol (2004) 1.26
Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res (2008) 1.26
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
Mechanisms of the development of androgen independence in prostate cancer. World J Urol (2005) 1.23
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res (2007) 1.23
The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res (2008) 1.21
20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer (2008) 1.21
Expression of cancer/testis antigens in prostate cancer is associated with disease progression. Prostate (2010) 1.21
The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. Prostate (2007) 1.20
Improved synthesis of histone deacetylase inhibitors (HDIs) (MS-275 and CI-994) and inhibitory effects of HDIs alone or in combination with RAMBAs or retinoids on growth of human LNCaP prostate cancer cells and tumor xenografts. Bioorg Med Chem (2007) 1.20
Genome-wide expression profiling reveals transcriptomic variation and perturbed gene networks in androgen-dependent and androgen-independent prostate cancer cells. Cancer Lett (2007) 1.20
The RNA-binding protein HuR opposes the repression of ERBB-2 gene expression by microRNA miR-331-3p in prostate cancer cells. J Biol Chem (2011) 1.20
"True" antiandrogens-selective non-ligand-binding pocket disruptors of androgen receptor-coactivator interactions: novel tools for prostate cancer. J Med Chem (2012) 1.19
Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med (2010) 1.19
Targeted ablation of the WW domain-containing oxidoreductase tumor suppressor leads to impaired steroidogenesis. Endocrinology (2008) 1.19
miR 488* inhibits androgen receptor expression in prostate carcinoma cells. Int J Cancer (2011) 1.19
Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome system. Angew Chem Int Ed Engl (2014) 1.18
The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum (1991) 7.94
Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med (2011) 7.62
Bisphenol-A: an estrogenic substance is released from polycarbonate flasks during autoclaving. Endocrinology (1993) 6.20
Advancing paternal age and the risk of schizophrenia. Arch Gen Psychiatry (2001) 3.48
The cognitive neuroscience paradigm: a unifying metatheoretical framework for the science and practice of clinical psychology. J Clin Psychol (2001) 3.45
Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med (2000) 3.26
Vascular complications after percutaneous coronary interventions following hemostasis with manual compression versus arteriotomy closure devices. J Am Coll Cardiol (2001) 2.74
Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes. J Clin Invest (1983) 2.25
Ketoconazole blocks adrenal steroid synthesis. Ann Intern Med (1982) 2.25
The decision-making value of magnetic resonance cholangiopancreatography in patients seen in a referral center for suspected biliary and pancreatic disease. Am J Gastroenterol (2001) 2.21
Inhibition of adrenal steroidogenesis by the anesthetic etomidate. N Engl J Med (1984) 2.16
Cognitive neuroscience and the progress of psychological science: once more with feeling (and other mental constructs). J Clin Psychol (2001) 2.16
Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science (1988) 2.15
The presence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican-American women. J Bone Miner Res (1996) 2.04
1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology (1981) 1.95
Distribution of a corticosteroid-binding protein in Candida and other fungal genera. J Gen Microbiol (1983) 1.86
Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res (1994) 1.85
The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr Rev (1999) 1.84
Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology (1993) 1.68
Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccidioides brasiliensis: implications for resistance of females to paracoccidioidomycosis. Infect Immun (1984) 1.65
Subcellular mechanisms in the action of adrenal steroids. Am J Med (1972) 1.65
Human renal isografts: a clinical and pathologic analysis. Medicine (Baltimore) (1968) 1.63
Replacement of liver function in rats by transplantation of microcarrier-attached hepatocytes. Science (1986) 1.61
Experimental and clinical applications of fibrin glue. Plast Reconstr Surg (1991) 1.60
A corticosteroid binding protein and endogenous ligand in C. albicans indicating a possible steroid-receptor system. Nature (1981) 1.55
Typhlocolitis in NF-kappa B-deficient mice. J Immunol (2001) 1.53
Estradiol binds to a receptor-like cytosol binding protein and initiates a biological response in Paracoccidioides brasiliensis. Proc Natl Acad Sci U S A (1983) 1.47
Adult onset polymyositis/dermatomyositis: an analysis of clinical and laboratory features and survival in 76 patients with a review of the literature. Semin Arthritis Rheum (1986) 1.43
The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American black and white women. J Bone Miner Res (1997) 1.43
An estrogen-binding protein and endogenous ligand in Saccharomyces cerevisiae: possible hormone receptor system. Science (1982) 1.42
Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) J Urol (1998) 1.40
Post-traumatic stress disorder in primary-care settings: prevalence and physicians' detection. Psychol Med (2001) 1.40
1alpha,25-Dihydroxyvitamin D3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res (2000) 1.39
Characterization of a unique corticosterone-binding protein in Candida albicans. J Biol Chem (1982) 1.37
Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res (2001) 1.36
Vitamin D resistant rickets with alopecia: cultured skin fibroblasts exhibit defective cytoplasmic receptors and unresponsiveness to 1,25(OH)2D3. J Clin Endocrinol Metab (1982) 1.36
Extensive polymorphism in the plasmodium vivax merozoite surface coat protein MSP-3alpha is limited to specific domains. Parasitology (2002) 1.32
Distinction between alpha-fetoprotein and intracellular estrogen receptors: evidence against the presence of estradiol receptors in rat bone. Endocrinology (1978) 1.30
Different types of calcium channels. J Exp Biol (1986) 1.30
The goals and limitations of Israel's psychiatric case register. Psychiatr Serv (1999) 1.29
An ochre mutation in the vitamin D receptor gene causes hereditary 1,25-dihydroxyvitamin D3-resistant rickets in three families. Proc Natl Acad Sci U S A (1989) 1.29
Candida albicans estrogen-binding protein gene encodes an oxidoreductase that is inhibited by estradiol. Proc Natl Acad Sci U S A (1994) 1.27
The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res (1998) 1.23
Estrogens from plastic--are we being exposed? Endocrinology (1997) 1.22
Concordance between childhood injury diagnoses from two sources: an injury surveillance system and a physician billing claims database. Inj Prev (2005) 1.21
Hereditary vitamin D resistant rickets caused by a novel mutation in the vitamin D receptor that results in decreased affinity for hormone and cellular hyporesponsiveness. J Clin Invest (1997) 1.17
Report from a forum on US heart allocation policy. Am J Transplant (2015) 1.17
Correlates of a perceived need for mental health assistance and differences between those who do and do not seek help. Soc Psychiatry Psychiatr Epidemiol (1999) 1.16
1,25-dihydroxyvitamin D3 receptors and hormonal responses in cloned human skeletal muscle cells. Endocrinology (1986) 1.15
Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol (2001) 1.14
Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J Clin Endocrinol Metab (2001) 1.14
MedEthEx Online: a computer-based learning program in medical ethics and communication skills. Teach Learn Med (2000) 1.14
Characterization of an estrogen-binding protein in the yeast Candida albicans. Endocrinology (1989) 1.13
A receptor-like binding macromolecule for 1 alpha, 25-dihydroxycholecalciferol in cultured mouse bone cells. J Biol Chem (1979) 1.12
Renal aldosterone receptors: studies with (3H)aldosterone and the anti-mineralocorticoid (3H)spirolactone (SC-26304). Proc Natl Acad Sci U S A (1974) 1.11
Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology (1999) 1.11
Regulation of 1,25-dihydroxyvitamin D3 receptors by vitamin D analogs in cultured mammalian cells. Endocrinology (1985) 1.11
Glucocorticoid receptors in rat kidney: the binding of tritiated-dexamethasone. Endocrinology (1973) 1.10
Effects of dexmedetomidine, a novel imidazole sedative-anesthetic agent, on adrenal steroidogenesis: in vivo and in vitro studies. Anesth Analg (1991) 1.09
Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. J Urol (1999) 1.08
Molecular modifications of anti-aldosterone compounds: effects on affinity of spirolactones for renal aldosterone receptors. Biochem Pharmacol (1974) 1.07
Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. J Clin Endocrinol Metab (1980) 1.07
Measurement of 1,25-dihydroxyvitamin D3 receptor turnover by dense amino acid labeling: changes during receptor up-regulation by vitamin D metabolites. Endocrinology (1987) 1.07
Cloning and expression of the gene from Candida albicans that encodes a high-affinity corticosteroid-binding protein. Proc Natl Acad Sci U S A (1993) 1.06
The molecular basis of hereditary 1,25-dihydroxyvitamin D3 resistant rickets in seven related families. J Clin Invest (1990) 1.06
Estradiol inhibits glucocorticoid receptor expression and induces glucocorticoid resistance in MCF-7 human breast cancer cells. J Steroid Biochem Mol Biol (2001) 1.05
Organ distribution of the cytoplasmic 1,25-dihydroxycholecalciferol receptor in various mouse tissues. Endocrinology (1980) 1.05
Search for inherited susceptibility to radiation-associated meningioma by genomewide SNP linkage disequilibrium mapping. Br J Cancer (2011) 1.03
1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol Cell Endocrinol (2000) 1.03
The anti-cancer and anti-inflammatory actions of 1,25(OH)₂D₃. Best Pract Res Clin Endocrinol Metab (2011) 1.02
Abnormal binding of vitamin D receptors to deoxyribonucleic acid in a kindred with vitamin D-dependent rickets, type II. J Clin Endocrinol Metab (1989) 1.01
Characterization of an estrogen-binding protein in the yeast Saccharomyces cerevisiae. J Biol Chem (1984) 1.01
Induction of androgen receptor by 1alpha,25-dihydroxyvitamin D3 and 9-cis retinoic acid in LNCaP human prostate cancer cells. Endocrinology (1999) 1.01
Homologous up-regulation of the 1,25 (OH)2 vitamin D3 receptor in rats. Biochem Biophys Res Commun (1986) 1.01
Bone response to titanium alloy implants placed in diabetic rats. Int J Oral Maxillofac Implants (2000) 1.00
1alpha,25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology (1997) 0.99
The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology (1973) 0.99
Characterization of a cytoplasmic receptor-like binder for 1 alpha, 25-dihydroxycholecalciferol in rat intestinal mucosa. J Biol Chem (1979) 0.99
Photoprotection by 1alpha,25-dihydroxyvitamin D and analogs: further studies on mechanisms and implications for UV-damage. J Steroid Biochem Mol Biol (2010) 0.99
Serum cartilage oligomeric matrix protein (COMP) levels in knee osteoarthritis in a Brazilian population: clinical and radiological correlation. Scand J Rheumatol (2007) 0.98
Ketoconazole binds to glucocorticoid receptors and exhibits glucocorticoid antagonist activity in cultured cells. J Clin Invest (1983) 0.98
Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3. Endocrinology (1995) 0.98
ACTH-independent massive bilateral adrenal disease (AIMBAD): a subtype of Cushing's syndrome with major diagnostic and therapeutic implications. Eur J Endocrinol (1994) 0.98
1 alpha,25-dihydroxyvitamin D3 receptors in cultured rat osteoblast-like cells. Glucocorticoid treatment increases receptor content. J Biol Chem (1983) 0.98
Cutaneous vasculitis in adult polymyositis/dermatomyositis. J Rheumatol (1983) 0.97
Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. J Rheumatol (1984) 0.96
Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells. Endocrinology (1993) 0.96
Vitamin D and prostate cancer. Endocrinology (2000) 0.96
Ultrastructural study of rat liver and liver neoplasms after long-term treatment with phenobarbital. Cancer Res (1981) 0.95
1alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology (2000) 0.95
Loss of alpha 2-macroglobulin and epidermal growth factor surface binding induced by phenothiazines and naphthalene sulfonamides. J Cell Physiol (1984) 0.94
Agonist and antimineralocorticoid activities of spirolactones. Am J Physiol (1976) 0.94
Ketoconazole and other imidazole derivatives as inhibitors of steroidogenesis. Endocr Rev (1986) 0.94
A novel mutation in the deoxyribonucleic acid-binding domain of the vitamin D receptor causes hereditary 1,25-dihydroxyvitamin D-resistant rickets. J Clin Endocrinol Metab (1996) 0.93
Identification of 17 beta-estradiol as the estrogenic substance in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A (1984) 0.92
Stress and intervention strategies in mental health professionals. Br J Med Psychol (1999) 0.92
A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr Med Res Opin (2003) 0.92
Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol (1999) 0.91
Glucocorticoid potentiation of the adenosin 3',5'-monophosphate response to parathyroid hormone in cultured rat bone cells. Endocrinology (1978) 0.91
Inhibition of steroidogenic cytochrome P-450 enzymes in rat testis by ketoconazole and related imidazole anti-fungal drugs. J Steroid Biochem (1985) 0.91